Clinical trials: Metabolic Dysfunction-associated Steatohepatitis
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Chronic Liver Disease and Cirrhosis
Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients…
- Trial name
- NCT07685353
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity & Overweight, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Adherence and Tolerability of Four Very Low-Calorie Ketogenic Diet Approaches in Adults With Obesity or Complicated Overweight
This study, called KOBE Study, looks at how well different very low-calorie ketogenic diets (VLCKD) are followed and tolerated by adults with obesity or complicated overweight in routine clinical practice.
- Conditions
- Obesity & Overweight, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Type 2 Diabetes, Insulin Resistance
- Trial name
- KOBE (NCT07389122)
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- University of Bologna
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Associated Fatty Liver Disease
Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease
This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.
- Trial name
- NCT05913986
- Testing
- LUDLEV®300 mg/46.2 mg
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Saluz Investigación S. C.
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in MASH patients with obesity and T2DM.
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT06492330
- Testing
- CS0159
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Liver Enzymes, Glucose Levels
Flaxseed Oil, Olive Oil, and Their Combination on Hepatic and Metabolic Outcomes in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
This 16-week randomized controlled trial evaluated the effects of flaxseed oil, extra virgin olive oil, and their combination on biochemical hepatic and metabolic outcomes in patients with MAFLD.
- Conditions
- Liver Enzymes, Glucose Levels, Lipid Profile
- Trial name
- NCT07837323
- Testing
- Conventional diet+treatment, flaxseed oil, extra virgin olive oil
- Where
- Pakistan
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Lahore
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
- Trial name
- NCT07848191
- Testing
- Rezdiffra, Resmetirom, ACTOS/pioglitazone
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
A Study of CS060380 Tablets in Patients With MASH and Obesity
this study is looking at a new investigational medicine called CS060380, when used together with semaglutide, in adults who have both metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
- Trial name
- NCT07466017
- Testing
- semaglutide, CS060380
- Where
- 12 sites in China
- Volunteers
- 130 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with…
- Trial name
- PERFORMA (NCT07795164)
- Testing
- Pemvidutide
- Where
- 9 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- Altimmune, Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT06768216
- Testing
- Indianized version of Mediterranean Diet, Low Fat Diet, Physical Activity
- Where
- India
- Volunteers
- 134 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Type 2 Diabetes
Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes.
- Trial name
- NCT06304844
- Testing
- transient elastography (Fibroscan)
- Volunteers
- 300 people
- Sponsor
- Sohag University
Steatohepatitis, Nonalcoholic
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
Primary outcome Screen for MAFLD among patients attending to the Nutrition clinic in Al Rajhi hospital. Secondary outcome Determining the degrees of fibrosis and steatosis in patients with MAFLD Determining the rate of obesity…
- Trial name
- NCT04861012
- Testing
- Ultrasound
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Assiut University
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Optimal Measurement of Spleen Stiffness Among Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
A growing number of people are being diagnosed with fatty liver disease, also known as metabolic-dysfunction associated liver disease (MASLD).
- Trial name
- NCT06953830
- Testing
- Vibration-controlled transient elastography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- William Jennings Bryan Dorn VA Medical Center
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated…
- Trial name
- MASLD-GUT (NCT07313007)
- Testing
- stool sampling, dietary assessment, and collection of blood and urine samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- STIRRED (NCT06944353)
- Testing
- STIRRED
- Where
- United States
- Volunteers
- 4,704 people
- Sponsor
- Northwestern University
MASH-related HCC
Long Term Prediction of MASH-related HCC Risk by Proteomics
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), affects over 25% of the global population and is increasingly associated with obesity and type 2 diabetes.
- Trial name
- PROTEOMASH (NCT07332611)
- Testing
- Proteomics
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Metabolic Dysfunction Associated Fatty Liver Disease
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves…
- Trial name
- NCT07285135
- Testing
- Glycine
- Where
- Singapore
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Helicobacter Pylori Infection Metabolic Dysfunction-Associated Fatty Liver Disease
Detection of Helicopacter Pylori in Patients With Metabolic Associated Fatty Liver Disease
Owing to the correlation between H.pylori and MAFLD, our study aims to search for H.pylori in every patient with MAFLD to aid in the management of MAFLD and improve quality of life for these patients by decreaseing morbidity and…
- Trial name
- HpyloriMAFLD (NCT07128147)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University